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Introduction
The standard treatment of early-stage non-small cell 
lung cancer (NSCLC) has been surgical resection when 
feasible. However, in patients who are surgically or 
medically inoperable or by patient preference, stereotactic 
body radiation therapy (SBRT) has become established 
as an effective definitive modality to treat stage I 
NSCLC (1), and it is emerging as a viable modality for 
medically operable patients (2). Many patients treated 
with SBRT have poor pulmonary reserve and significant 
co-morbidities and are, therefore, also at significant 
risk of developing complications from biopsy. While a 
historical resolute mantra of cancer care is that no therapy 
is administered without pathologic proof of malignancy, 
clinicians are increasingly faced with the challenge of 
considering SBRT to be performed empirically for patients 
with radiographic findings consistent with early-stage 
lung cancer. We performed a thorough literature search 
and formed the Empiric Radiotherapy for Lung Cancer 
Collaborative Group to report the evidence regarding 
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empiric SBRT and guidelines for physicians to consider. 
Herein, we provide an expert commentary on how to apply 
“rationalism to empiricism,” or when it is appropriate to 
treat a patient with SBRT without pathologic confirmation. 
Scope of the problem
Lung cancer is the leading cause of cancer-related death 
in the United States in both men and women, with an 
estimated 154,050 deaths annually (3). The National 
Lung Screening Trial (NLST) randomized asymptomatic 
patients at high risk for lung cancer to either low-dose 
CT (LDCT) or chest radiography and found that LDCT 
identified more cases of lung cancer (1.1% vs. 0.7%) 
with a sensitivity and specificity of 93.8% and 73.4%, 
respectively (4). This study led to numerous professional 
organizations rapidly endorsing screening, including 
the United States Preventative Services Task Force 
(USPSTF) (5). Despite this recommendation, lung cancer 
screening is only slowly being adopted due to concerns 
over resources, radiation dose, and cost-effectiveness (5). 
The question of when to perform empiric SBRT will 
become increasingly critical in the era of screening (6-9). 
Also important is to recognize that false positive results 
were noted in 96.4% of the positive screening results in the 
LDCT group of the NLST. As such, there is great need to 
establish guidelines to improve the predictive yield of an 
abnormal screening result, with special reference to patients 
at high risk of invasive diagnostic complications and hence 
referred for empiric SBRT.
Indications for SBRT and accompanying risks 
and benefits
SBRT has emerged as a standard of care for inoperable 
stage I NSCLC with highly effective control of the primary 
tumor, but, like surgery, it similarly carries a challenging 
5-year disease free survival of 45–63% (10-13). A pooled 
analysis of two randomized trials (STARS, ROSEL) of 
SBRT versus surgery in operable patients found equal 
relapse-free survival, although overall survival (OS) was 
improved in the SBRT arm potentially due to excessive 
toxicities associated with surgery (14). Therefore, while the 
most accepted use of SBRT is in the inoperable population, 
SBRT is increasingly being considered in the operable 
population as additional trials in medically operable patients 
are reported (15). 
SBRT, while generally very well tolerated, carries a low 
risk of adverse events (16), including pneumonitis (17), 
chest wall pain syndrome and rib fracture for peripheral 
lesions (18), and concern for great vessel or airway 
injury for central tumors, defined as within 2 cm of the 
tracheobronchial tree (19). The concern for potentially 
lethal toxicity is greatest for central lesions and especially 
ultra-central lesions (20), although recent evidence supports 
safe fractionation for central lesions (21). Therefore, 
location can be one consideration for whether or not to 
perform empiric SBRT. It is also important to note that 
many patients with central or ultra-central lesions who 
are at a higher risk of toxicities from radiation are also not 
candidates for sub-lobar resections. SBRT, therefore, is 
an important aspect of curative intent treatment for these 
patients, with or without pathological diagnosis. In these 
guidelines, we only discuss the management of non-central 
lesions, as the risk-benefit ratio will be defined with evolving 
results from the prospective NRG Oncology RTOG 
0813 trial.
With increasing diagnoses of early stage lung cancer, 
clinicians are often faced with the question of surgery 
without a biopsy or empiric SBRT. Surgery provides a 
pathologic diagnosis (PD) and simultaneous lymph node 
analysis, and this information can guide therapeutic 
decision making such as conducting molecular analysis 
and need for adjuvant therapy. Most importantly, the vast 
majority of lung nodules identified are not lung cancer, 
with the positive predictive value in a high-risk population 
of the NLST of only 2.4% (4). Therefore, overtreatment 
of benign nodules with SBRT remains a potential concern. 
Another common clinical scenario is for patients who have 
undergone a prior surgical (lobar or sub-lobar) resection 
or SBRT with preceding tissue confirmation and are noted 
to have serial enlargement or development of a new lung 
nodule radiographically consistent with a new primary 
lung cancer. In this setting, proceeding with SBRT without 
an attempted biopsy in select patients can be a reasonable 
option since the risks of biopsy may be higher in patients 
having undergone prior surgery and the likelihood of cancer 
may be higher given the prior personal history of lung 
cancer in these patients.
In patients not undergoing definitive resection, histologic 
confirmation can be obtained via a transthoracic computed 
tomography-guided needle biopsy or via a transbronchial 
biopsy, which allows for simultaneous nodal evaluation via 
endobronchial ultrasound (EBUS) (Table 1). In addition to 
providing definitive diagnostic confirmation and staging, 
tissue diagnosis also may also allow for prognostication 
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between NSCLC histologies (22) and between NSCLC 
and early stage small cell lung cancer (23) which can guide 
subsequent decisions for systemic therapy (24). However, 
arguments can be made against obtaining a pre-treatment 
histologic diagnosis. First, transthoracic computed 
tomography-guided needle biopsy carries approximately 
a 20% risk of pneumothorax and a 5% risk of serious 
complications such as chest tube placement. These risks 
can be as high as 35% and 10.7%, respectively, in a 
typical medically inoperable patient or those with limited 
pulmonary reserves (25). The diagnostic yield of a biopsy 
varies widely in the literature between 64–95%, so the 
risk of the procedure may be incurred without obtaining 
a definitive tissue diagnosis. If a patient subsequent to 
SBRT develops a recurrence, a biopsy can be performed 
on the recurrence, which may present in a more amenable 
location to biopsy and may be more molecularly insightful 
in guiding subsequent therapies than would a biopsy at the 
time of initial diagnosis. 
Existing literature supporting empiric SBRT
There have been several publications examining the clinical 
outcomes of empiric SBRT (14,26-32) (Table 2). Although 
there are no specific prospective trials examining empiric 
versus biopsy-confirmed SBRT, many large prospective 
studies permitted patients to be enrolled without a 
biopsy, including the ROSEL trial (14), although most 
trials required biopsy-proven malignancy, such as in RTOG 
0236 (11). As shown in Table 2, inoperable patients comprise 
62–88% of the population in these retrospective studies. 
Toxicity rates, a critical consideration in empiric SBRT, are 
low, including radiation pneumonitis and rib fractures (<5%) 
(26,27). In the two studies of 398 and 591 patients who had 
a PD versus no PD [clinical diagnosis (CD)], no differences 
in local control (LC), progression-free survival (PFS), or 
OS were identified, supporting the hypothesis that most of 
these CD patients who were empirically treated truly did 
have lung cancers (28,29). 
Tools available for predicting the probability of 
malignancy 
To quantify a given patient’s pretest probability of 
malignancy, multiple tools have been studied. In the 
screened population, a calculator was developed from the 
Pan-Canadian Early Detection of Lung Cancer Study and 
validated through the British Columbia Cancer Agency. 
Predictors of malignancy included older age, female sex, 
family history of lung cancer, emphysema, larger nodule 
size, location of the nodule in the upper lobe, part-solid 
nodule type, lower nodule count, and lesion spiculations. 
Their model had an impressive area under the receiver 
operating characteristic curve (AUC) of 0.94, even for small 
nodules (33).
There have also been prediction models developed in 
the non-screened population, where the prevalence of lung 
cancer diagnosed after imaging is higher (34). Investigators 
from the Mayo Clinic examined patients with non-
calcified nodules between 4 and 30 mm in diameter, with 
risk calculated for age (OR 1.04), smoking history (2.2), 
extra-thoracic cancer <5 years before nodule detection 
(3.8), nodule diameter (1.14/mm), spiculations (2.8), and 
upper lobe location (2.2) (35,36). While positron emission 
tomography (PET) imaging can have clear benefits in 
diagnosis, staging, prognostication, and target volume 
Table 1 Benefits of pathology-proven and empiric SBRT 
Benefits of pathology-proven SBRT Benefits of empiric SBRT
Confirmation of malignancy Avoid CT-guided transthoracic needle biopsy which for peripheral 
tumor which can be non-diagnostic in 5–35% of cases 
Pathology for guidance of systemic therapy (i.e., small cell carcinoma 
or future therapies)
No risk of pneumothorax 
If transbronchial biopsy is an option (i.e., central disease), EBUS 
nodal evaluation can be performed simultaneously
Safer than biopsy in patients on blood thinners, with tumors in 
difficult to biopsy locations, with numerous comorbidities
Avoid unnecessary SBRT if pathology is negative for malignancy Biopsy can be obtained at relapse if needed
Increased cost-effectiveness (avoiding overtreatment of benign 
nodules)
–
SBRT, stereotactic body radiation therapy; EBUS, endobronchial ultrasound.
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delineation in lung cancer (37-39), Herder et al. performed 
an external validation model of this Swensen analysis on 
the added value of 18-FDG PET and did not find the 
AUC was significantly different from the model without 
PET (40). In summation, studies have shown that these 
models are similar in accuracy to clinical judgment (41), but 
overall physicians tend to somewhat overestimate the risk of 
malignancy. 
Determining the appropriate pretest probability 
threshold for empiric SBRT 
The pretest probability threshold above which it is 
acceptable to perform a therapeutic procedure in this 
setting, either surgery or SBRT, is not well-defined. The 
American College of Chest Physicians (ACCP) Evidence-
based Clinical Practice Guidelines states that it is reasonable 
to consider SBRT above a pretest probability of 65% (34); 
however, other organizations have suggested a higher 
threshold, including the International Association for the 
Study of Lung Cancer (IASLC) suggesting that no more 
than 15% of surgical specimens resulting from a positive 
screened population should result in benign findings (8) 
(Table 3). Despite this recommendation, 25% of procedures 
performed in the NLST had benign findings (4), and the 
positive predictive value was only 3.8% for 4 mm or larger 
nodules. These threshold differences in pre-test probability 
previously recommended between surgical and SBRT 
populations may, in part, be based on differences in toxicity 
profiles between surgery and SBRT. 
The question of an appropriate threshold has also been 
examined specifically within the context of SBRT. Louie 
et al. constructed a decision tree and Markov model to 
evaluate the relative merits of surveillance, a PET-directed 
SBRT strategy (without pathology), or a PET-biopsy-SBRT 
strategy. They found that the threshold between the two 
strategies was 85%, which they confirmed on probabilistic 
sensitivity analysis. The threshold was most sensitive to 
the diagnostic sensitivity of transthoracic biopsy and the 
detection rate of false negatives on CT surveillance (42). 
This is in keeping with the threshold of IASLC and that has 
been proposed by other investigators (43).
Understanding the combination of clinical and 
radiographic findings recommended before 
performing empiric SBRT
As is detailed below, appropriate patient selection for 
SBRT should be based on a combination of clinical and 
radiographic findings, including interval lesion growth, size 
of the suspected malignancy, radiographic appearance of the 
nodule, patient smoking and prior lung cancer history, and 
FDG avidity on PET/CT. 
Staging procedures recommended for patients undergoing 
empiric SBRT
In addition to CT chest and PET imaging, NCCN 
guidelines recommend MRI brain for all patients with a 
 ≥3 cm lesion. A recent institutional report identified a 2.4% 
risk of asymptomatic brain metastases in tumors <3 cm and 
5.6% in tumors up to 5 cm who were radiologically node 
negative (44). None of the stage II patients were found 
to have brain metastases, whereas 6.1% of stage IIIA had 
asymptomatic brain disease. As such, while we recommend 
that all empiric SBRT patients with lesions >3 cm undergo 
MRI brain, the requirement could potentially be relaxed 
for PET-CT and pathologically confirmed node negative 
patients with tumors >3 cm but ≤5 cm. Whenever feasible, 
we recommend nodal staging with EBUS for all lesions, 
acknowledging that it may be acceptable to forego this 
procedure in patients with no evidence of radiographically 
Table 3 Proposed acceptable pretest probability thresholds for empiric therapy for clinical stage I non-small cell lung cancer 
Study
Proposed acceptable pretest probability 
thresholds (%)
PET/CT included in threshold calculation?
Gould et al. (34) 65 No
Louie et al. (42) 85 Yes
IASLC (8) 85 No
Senan et al. (43) 85 Yes
PET, positron emission tomography.
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enlarged or metabolically active lymph nodes on diagnostic 
CT chest and PET/CT, respectively, and especially in 
those with <2 cm lesions and peripherally located lesions 
(34,45,46). Patients should also undergo pulmonary 
function testing to better assess their risk of pulmonary 
complications from treatment and basic laboratory studies 
to evaluate for an active infection that could be presenting 
falsely on imaging as a clinical lung cancer.
Considerations for empiric SBRT for suspected tumors 
>3 cm
If a suspected tumor is >3 cm and identified on either a 
screening or non-screening scan, it is considered a mass 
and is malignant until proven otherwise, although still it 
is important to recognize that that many lesions >3 cm 
are benign. PET/CT should be obtained. If the tumor is 
FDG-avid, a biopsy cannot be safely obtained, and there 
is no clinical suspicion for a benign process, we suggest 
proceeding with empiric SBRT. If the mass is not FDG-
avid, it is much less likely to be malignant. In such cases, 
we recommend further workup for a benign process and, 
if no diagnosis is obtained, short-interval serial imaging. 
As SBRT is increasingly being considered in tumors 
>5 cm, these same considerations can be applied (47,48). 
However, as the risk of nodal failures is particularly high in 
patients with large primary tumors with radiographically 
negative nodal disease (49), nodal sampling with primary 
tumor biopsy should be considered whenever clinically 
feasible. 
Empiric SBRT for solitary pulmonary nodules ≤3 cm
There are multiple approaches to consider in the evaluation 
of patients with solitary pulmonary nodules ≤3 cm. First, we 
can consider the AACP division of nodules. They separate 
their management recommendations into solid nodules 
>8 and ≤8 mm. For nodules >8 mm, if the risk of malignancy 
is 5–65%, they recommend PET/CT be performed. If the 
risk if >65%, they recommend against PET/CT and instead 
recommend a surgical diagnosis. Surgical diagnosis should 
also be pursued if the nodule is FDG-avid on PET or 
positive by another functional imaging test and when a fully 
informed patient prefers a definitive diagnostic procedure. 
As shown in Table 3, many advocate instead for a clinical 
probability threshold of >85%, and we agree this is a good 
threshold. If the pretest probability using the Mayo Clinic 
calculator is >85%, then it is likely acceptable to proceed 
with empiric SBRT (32). If the pretest probability is 
between 65% and 85%, PET/CT is a reasonable approach, 
and, if FDG-avid to proceed with SBRT. If the nodule is 
not FDG-avid, patients can undergo short-interval CT at 
3 months, and clinicians should use the volume doubling 
time (VDT) guidelines as described below. 
An alternative approach is to use the more recently 
developed Lung-RAD® system (Table 4), which was created 
by the American College of Radiology in 2014 as a lexicon 
to describe lung nodules on screening (50). They increased 
the size of a positive non-solid (ground-glass) nodule to 
2 cm from 6 mm, and the nodule can be considered benign 
if stable over 3 months (versus 2 years in the NLST). Lung-
RAD® has been shown to increase the positive predictive 
value in CT-screened patients by a factor of 2.5, to 17.3%, 
without increasing the number of false-negative results (51). 
Patients who fall into Lung-RAD® category 4A or 4B can 
undergo PET/CT. 
If the nodule is FDG-avid (SUV ≥2), then empiric SBRT 
is a reasonable approach. If it is not FDG-avid, then serial 
observation is likely reasonable. Based on the NELSON 
CT-screening study, the lesion was considered positive if 
it had growth on serial scans (defined in this study as 25% 
growth by volume) and if the VDT was <400 days, or if a 
Table 4 Lung-RAD® suspicious categories
Category Finding
4A Solid nodule(s): ≥8 to <15 mm at baseline or growing <8 mm or new 6 to <8 mm
Part solid nodule(s): ≥6 mm with solid component ≥6 mm to <8 mm or with a new or growing <4 mm solid component
Endobronchial nodule
4B Solid nodule(s): ≥15 mm or new or growing, and ≥8 mm
Part solid nodule(s) with: a solid component ≥8 mm or a new or growing ≥4 mm solid component
4X Category 3 or 4 nodules with additional features or imaging findings that increases the suspicion of malignancy
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new solid component had emerged in a previously non-
solid nodule (52). Therefore, if the projected VDT is 
<400 days based on short-interval scan, the argument for 
empiric SBRT is further strengthened. In summary, if the 
pretest probability is >85% based on any calculator, then 
empiric SBRT is an acceptable option. 
Empiric SBRT for ground glass nodules
For pure ground glass nodules without a solid component, 
the AACP recommends annual surveillance for nodules 
>5 mm. For larger, part-solid but >50% ground glass 
nodules, lesions should be managed as solid nodules 
>8 mm (34), and thus managed according to the discussion 
above.
Conclusions
We have attempted to apply rationalism to empiricism; we 
have discussed the strongest evidence currently available 
and clinical considerations regarding the often-encountered 
and challenging situation of empiric SBRT for patients 
with peripheral clinical stage I NSCLC, where biopsy 
confirmation is too high-risk from a pulmonary function 
perspective or unable to be obtained safely for other 
medical or accessibility reasons. We have discussed the 
scope of the problem and the risks and benefits of empiric 
SBRT, and we defined the appropriate pretest probability 
threshold and tools available for predicting this threshold. 
We provide considerations and recommendations for the 
clinical and radiographic findings to warrant empiric SBRT, 
and we divide our recommendation first by size, taking into 
account recent data from the screened and non-screened 
populations. 
We endorse the American Society for Radiation 
Oncology guidelines on SBRT for early stage NSCLC 
recommending that a biopsy prior to SBRT be obtained 
whenever possible to confirm a histologic diagnosis of 
malignancy (53). We also recommend that patients without 
tissue confirmation of malignancy should be discussed in a 
multidisciplinary manner to reach a consensus on whether 
the lesion is radiographically and clinically consistent 
with a lung cancer. The decision to proceed or not 
proceed with empiric SBRT must be an individualized and 
multidisciplinary decision, taking into account patient- and 
tumor-specific factors as outlined in these guidelines. Future 
research will help further define the pretest probability and 
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